Form 4: Galectin Therapeutics Director Eldred Kary Reports Stock Purchase

Director Eldred Kary of Galectin Therapeutics reports purchasing 400 shares of common stock at $2.39 per share.

Summary

• On January 16, 2024, Eldred Kary, a director of Galectin Therapeutics, purchased 400 shares of common stock at a price of $2.39 per share.
• Following this transaction, Kary directly owns 49,713 shares of Galectin Therapeutics common stock.
• Kary also indirectly owns 2,425 shares as a UTMA custodian for a minor child and 2,000 shares held in trust.
• Kary disclaims beneficial ownership of the shares held as custodian and in trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, the quantity is not significant enough to drastically alter sentiment.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track confidence levels and potential alignment of interests.

Stakeholder Impact

• The stock purchase by a director could have a slightly positive impact on shareholder sentiment.

Key Dates